Mon, Apr 21, 2014, 4:51 AM EDT - U.S. Markets open in 4 hrs 39 mins


% | $
Quotes you view appear here for quick access.

Celsion Corp. Message Board

asicprof 2 posts  |  Last Activity: Apr 9, 2014 10:45 PM Member since: Nov 19, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to


    by asicprof Apr 9, 2014 2:00 AM
    asicprof asicprof Apr 9, 2014 10:45 PM Flag

    Few posters are trying to divert the topic by attacking my English . We area family from a non English speaking European country. We are working on arranging an interview from Top-notch STS doctors to discuss P2 results .
    We will shortly see large positions from well know Hedge funds like Baker BROS and others.
    None of the fund is worried about all this Dream team drama , in-fact some of them welcomed this drama as it provided them an opportunity to load more on low PPS.

    GBM enrollment is going smoothly , we might see interim resultss as soon as July-14.
    Even a 10% reduction in tumor will be sufficient to gain BTD for GBM indication . Also CYTR is going to announce STS p2 survival number in ASCO .....that will be a big catalyst.

    Partnership announcement may come any time .
    This stock could be a $30 stock in 2015.

  • Disclaimer : We are long CYTR , holding 1.2M share .

    Our team did a through research of CYTR and took a position . Out research team consisted of Doctors (MD) , PHD , former BP executive and very experienced biotech analyst .We are extremely confident of our position in CYTR, In fact current PPS is offering a one of the most lucrative investing opportunity in Biotech history.

    Recent short attack was meticulously planed to shake out trader , and weak hand who bought stock with margin account . This is typical bio-tech phenomena . MM are working for their institutional clients to fulfill their large orders by shaking out weak retails .

    Out research team reviewed all the articles from Dream Team and we found that all the information in the articles is consistent of with our bullish view. All the data points and future valuation model in the articles are correct.

    We assign almost 70% chance of P3 success based on the outstanding P2 result , but this stock may not wait for P3 result , the run-up may start on GBM interim results . We think that Aldo will shows efficacy and GBM and FDA will grant BTD (Break through designation) to Aldo.

    Stock may trade to north of $15 if Aldo gets BTD. A monster run may start in the beginning of June as GBM P2 enrollment completes .

    CYTR is the life time opportunity if one has stomach to hold the stock for 1 year.
    At $3.3 , CYTR is extremely cheap given that they have almost $2.4 worth of cash.

    Do your own DD.
    We are adding more in our position at these levels.

    Sentiment: Strong Buy

3.27+0.14(+4.47%)Apr 17 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
AstraZeneca PLC
NYSEThu, Apr 17, 2014 4:00 PM EDT
Urban Outfitters Inc.
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT